History

Thymalin comes from the Soviet/Russian peptide-bioregulator program associated with Vladimir Khavinson and Vladimir Morozov. Some sources place the original development at the Military Medical Academy in Leningrad (St. Petersburg) in the 1970s, with later work at the St. Petersburg Institute of Bioregulation and Gerontology; both attributions are reasonable. It was approved by the USSR Ministry of Health for medical use in 1982 (Order No. 1008 of 10.11.1982) as an immunomodulator, and three short peptides — KE (Vilon), EW (Thymogen), and EDP (Crystagen) — were later isolated from or derived from it. Most published research on the preparation comes from this single research lineage, with little independent replication outside Russia.

Thymalin is a thymus-extract peptide preparation from the Russian “bioregulator” tradition, marketed online as an immune-restoring, anti-aging compound. It has more genuine clinical history than most research peptides — including a Soviet-era approval that still stands in Russia — but the human evidence is thin, small, largely non-blinded, and almost entirely from the people who developed it. It is also easy to confuse with two unrelated thymic-named drugs, so precision matters here.

What it is

Thymalin is a polypeptide complex extracted from the thymus gland of calves (bovine), not a single defined molecule. It belongs to the family of “Khavinson bioregulators” or cytomedines developed in the USSR. Researchers later identified three short active peptides within or derived from it — KE (Lys-Glu, “Vilon”), EW (Glu-Trp, “Thymogen”), and EDP (Glu-Asp-Pro, “Crystagen”). The proposed mechanism is immune/thymic restoration: supporting T-cell maturation and normalizing CD4/CD8/NK-cell populations. The originators also hypothesize an epigenetic, gene-regulatory action in which short peptides bind DNA or histones to modulate transcription — but that “peptide binds dsDNA” model is largely their own hypothesis, not independently established mechanistic consensus.

A note on names: Thymalin is not Thymosin alpha-1 (thymalfasin), a separate, defined, single-molecule drug approved in some countries for hepatitis. It is also not Thymosin beta-4 / TB-500. The shared “thymus” branding causes constant confusion; the three are different substances with different evidence and different regulatory status.

The claims

Vendors and blogs promote Thymalin as an immune-system “reset” that restores thymic function, rejuvenates aging immunity, extends lifespan, and protects against infection. Some of the boldest figures circulating online — for example “45% cardiovascular mortality reduction,” “28% PD-1 drop in 120 adults,” “6.8-fold immune regeneration,” or “the longest peptide trial ever” — are vendor or blog phrasings that do not appear in the primary literature. Treat those as marketing, not as findings.

What the evidence actually shows

The human data is real but limited, and it clusters around one research group.

The most-cited study is Khavinson & Morozov (2003), which followed 266 elderly subjects for 6–8 years (peptides given in the first 2–3 years) and reported a roughly 2.0–2.1-fold mortality reduction with Thymalin alone, and up to 4.1-fold with repeated combined Thymalin plus Epithalamin dosing. The caveats are large: it was conducted in Russia, is decades old, is not a blinded modern RCT by Western standards, is small for a mortality endpoint, was never independently replicated outside Russia, and comes from the compound’s originators. Read it as hypothesis-generating, not established.

During the pandemic, Kuznik, Khavinson et al. (2021) ran a prospective, randomized, single-blind controlled trial in severe COVID-19 in older patients at a single center in Chita, Russia (Thymalin n=36 vs. control n=44). It reported faster normalization of lymphocyte, NK-cell, and T-cell counts and lower hospital mortality — 7/36 (about 19.4%) versus 18/44 (about 40.9%). Again the caveats dominate: single-center, small, single-blind, in Russia, and unreplicated. Notably, no verifiable ClinicalTrials.gov (NCT) registration exists for this Thymalin trial — the COVID NCT records that get linked to it (such as NCT04487444, the Rhode Island Hospital pilot) are actually Thymalfasin / thymosin alpha-1 studies, a different drug. (Some write-ups attach a “p=0.039” to the mortality difference; the raw event rates check out, but that exact p-value could not be independently confirmed, so it is best left out.)

A 2021 review by Khavinson and colleagues summarizes reduced acute respiratory illness in the elderly and small immunogram-normalization studies — but it is a narrative review by the originators, not independent primary RCT evidence. The remaining mechanistic and “geroprotection” claims rest on the same group’s animal, cell, and short-peptide work, which Western groups have not independently corroborated.

Bottom line on the evidence: human data exist, but they are thin, geographically and authorship-concentrated, small, mostly non-blinded or single-blind, and unreplicated. That is enough to be interesting, not enough to be established.

Legal and regulatory status

In Russia, Thymalin was approved by the USSR Ministry of Health in 1982 (Order No. 1008, 10.11.1982) and has been used as an immunomodulator. This is a Russian national registration, which uses lower evidentiary thresholds than a US New Drug Application — it is not equivalent to FDA approval.

In the United States, Thymalin is not FDA-approved for any indication, and the FDA has never reviewed it. It is not a dietary supplement and has no cosmetic-ingredient standing in the US or EU; US vendors sell it only as a “research chemical / not for human use.” In practice it is research-grade or foreign-registered, not an approved medicine.

For athletes: Thymalin is not named on the WADA Prohibited List. But WADA prohibits by category, not only by name, and S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) contains catch-all language for substances with similar biological effect. For calibration, the commonly banned thymic-named peptide is Thymosin-β4 / TB-500, which is on the list under S2, prohibited at all times. Because of the catch-all framing and the injectable route, athletes should treat Thymalin as high-risk / presumptively prohibited and seek a TUE or a governing-body ruling rather than assume it is allowed.

Safety

Human safety data are limited and come mainly from Russian clinical use; no rigorous Western safety or pharmacovigilance dataset exists. Because it is a biologic extracted from bovine thymus tissue, it carries the category risks of animal-tissue extracts: product purity, batch-to-batch variability, allergenicity and immunogenicity, and contamination. “Research-grade” vials carry no sterility or identity guarantees.

Long-term safety, drug interactions, and the consequences of chronically modulating immune and T-cell signaling are not well characterized. Given that mechanism, there are theoretical concerns for anyone with autoimmune disease, immunosuppression, or malignancy. This is not an established consumer or “biohacking-safe” compound, and nothing here is medical advice.

Bottom line

Thymalin is a genuinely studied Russian thymic-peptide preparation with a real Soviet-era approval and a handful of small human studies suggesting immune normalization and lower mortality in the elderly and in severe COVID-19. But that evidence is thin, small, mostly non-blinded, concentrated in a single research lineage, and unreplicated outside Russia — and the flashiest figures online are not in the primary literature at all. It is not FDA-approved, it is sold only as a research chemical, and it should not be confused with Thymosin alpha-1 or TB-500.

Evidence grade: Preliminary human.